How Often Should You Get the Shingles Vaccine?

For most adults, the shingles vaccine requires just two doses, spaced two to six months apart, with no booster currently recommended. The vaccine in question is Shingrix, a recombinant adjuvanted vaccine that replaced the older live vaccine (Zostavax) and is now the standard worldwide. Clinical trial data tracking recipients for nearly a decade show that protection remains strong years after the initial series, which is why health authorities have not yet added a booster to the schedule. But “not yet” is doing real work in that sentence, and the details matter depending on your age, immune status, and how long ago you were vaccinated.

The Standard Two-Dose Schedule

Shingrix is given as two intramuscular injections. The second dose is recommended two to six months after the first. You do not need to restart the series if more time passes between doses; a delayed second shot still counts. This two-dose course is the entire recommended schedule for healthy adults aged 50 and older in the United States, and no additional doses are on the books.

Getting both doses matters more than most people realize. A single dose provides some short-term protection, but the immune response roughly doubles after the second shot, and the durability of that response depends heavily on completing the pair. Real-world adherence data from over 700,000 U.S. adults found that about 72% got their second dose within the recommended six-month window, and that figure climbed to about 86% when people were given up to two years to come back for it.¹ That still leaves a meaningful minority walking around with incomplete protection, which is one reason the “how often” question gets muddled with the “did you finish the series” question.

How Long Does Protection Last?

The strongest evidence comes from long-term follow-up of the two large pivotal trials that got Shingrix approved. An interim analysis tracking participants out to roughly ten years after vaccination found that overall efficacy against shingles was about 89% when measured from the original vaccination date. Annual efficacy estimates stayed above 83% through year eight, then settled to around 73% in years nine and ten.²

An earlier look at the same cohort, published when the data reached roughly seven to eight years of follow-up, reported annual efficacy above 84% for every year since vaccination, with immune markers plateauing at about six times their pre-vaccination levels.³ So protection does gradually wane, but it wanes slowly and from a very high starting point. Even in the tenth year, the vaccine still prevented roughly three out of four shingles cases compared to no vaccination at all.

That trajectory matters for the booster question. A vaccine that drops from 90-something percent to the low 70s over a decade is still working hard, but the trend line suggests that at some point beyond ten years, a booster dose could meaningfully restore protection. Researchers and regulators are watching this space, and ongoing follow-up studies are extending the data further. A cost-effectiveness analysis found that a booster dose would be most economically justifiable at around ten years after the initial series.⁴ That does not mean a booster is recommended today, but it gives a sense of the timeline scientists are thinking about.

Why No Booster Is Recommended Yet

Regulatory agencies generally do not add a booster to a vaccine schedule until two things happen: protection drops to a level where the disease burden becomes unacceptable again, and clinical trial data demonstrate that a booster dose safely restores immunity. For Shingrix, the first condition has not been met yet. Protection in the low 70s at year ten is still substantial, and no trial of a third dose has been completed and published in a way that would let an advisory committee vote on it. Cost-effectiveness modelers have noted that continued assessment of long-term protection is needed before the potential need for booster doses can be properly evaluated.⁵

If you were vaccinated five or six years ago and are wondering whether you should get another round, the honest answer right now is no, not based on current guidelines. That could change in the next few years as the decade-plus follow-up data mature and if efficacy continues to decline at the rate observed so far. For now, the practical advice is straightforward: get the two-dose series if you haven’t, finish it if you only got one, and watch for updated guidance if it has been more than ten years since your second dose.

What About People Who Already Had Shingles?

Having a shingles outbreak does not exempt you from vaccination. Shingles can recur, and vaccination after a bout is both safe and recommended. The question is timing. A study that compared immune responses in people vaccinated at different intervals after a shingles episode found that the vaccine worked similarly whether it was given six to twelve months after illness or more than a year later.⁶ Most clinicians suggest waiting until the rash has fully resolved and you are feeling well again before getting vaccinated, but there is no need to wait years.

The same two-dose schedule applies after a shingles episode. You do not get extra doses because you had an outbreak, and you do not get fewer. The virus is still latent in your nerve cells, and the vaccine’s job is to keep your immune system vigilant enough to prevent it from reactivating again.

If You Are Immunocompromised

People with weakened immune systems face a higher risk of shingles and its complications, and this is exactly the group where vaccination becomes both more important and more nuanced. A meta-analysis of clinical trials in immunocompromised populations found that Shingrix reduced shingles incidence by about 81%, though the immune response was somewhat lower in organ transplant recipients and people with a history of cancer.⁷ The vaccine’s effectiveness against postherpetic neuralgia, the chronic nerve pain that can follow a shingles outbreak, was notably lower in immunocompromised people than in the general population: roughly 39% compared to about 85% in people with healthy immune systems.⁸

Safety data from pooled trials in immunocompromised adults, including people who had received stem cell transplants, organ transplants, or treatment for blood cancers and solid tumors, found no significant difference in serious adverse events between the vaccine and placebo groups.⁹ Because Shingrix is not a live vaccine, it can be given to people on immunosuppressive therapies, which was not the case with the older Zostavax. The dosing schedule is the same two doses, though timing may need to be coordinated around chemotherapy cycles or transplant medications. Whether this group will eventually need boosters sooner than the general population is an open question, given the lower initial immune response.

Side Effects and Why They Scare People Off

Shingrix has a reputation for being a rough ride, and the data back that reputation up to a point. In pooled analysis from the pivotal trials, about 78% of vaccine recipients reported injection-site pain, and roughly 45% each reported muscle aches and fatigue.¹⁰ Headache affected about 38%. These numbers are dramatically higher than the placebo arm, so the vaccine is genuinely causing these symptoms, not just catching background noise. The saving grace is that most symptoms are mild to moderate and resolve within two to three days.

Serious side effects were not more common in vaccine recipients than in placebo recipients in those same trials. The distinction between “reactogenicity” and “safety” is worth understanding here. Reactogenicity means the short-term, self-limiting symptoms your body produces as it mounts an immune response: sore arm, tiredness, muscle aches. Safety refers to serious events like hospitalization, lasting harm, or death. Shingrix scores poorly on reactogenicity and well on safety. The same pattern held in trials of immunocompromised patients, including those with blood cancers, where vaccine recipients reported more soreness and fatigue but no more serious events than those who got placebo injections.¹¹

The problem is that the unpleasantness of those short-term symptoms discourages people from coming back for the second dose, or from starting at all. In one survey of adults 50 and older, concerns about tolerability were the leading reason both for not starting the series and for not completing it. Among unvaccinated respondents, 46% cited concerns about how the vaccine would make them feel. People who were worried about side effects were nearly twice as likely to stop at one dose instead of finishing the series.¹² This is a real public health challenge: a vaccine that works extremely well but makes a day or two fairly uncomfortable ends up underused because people dread the aftermath more than they fear the disease.

Can You Get Shingrix at the Same Visit as Other Vaccines?

Yes. A randomized controlled trial tested co-administration of Shingrix with either an mRNA COVID-19 vaccine or an adjuvanted influenza vaccine and found that giving them at the same visit did not reduce the immune response to any of the vaccines. The antibody levels generated by Shingrix were essentially identical whether it was given alone or alongside the COVID or flu shot, and the same was true in the other direction: the COVID and flu vaccines worked just as well when given at the same time as Shingrix.¹³ If you are due for a flu shot or a COVID booster, there is no immunological reason to space them out from your Shingrix dose. Practically, getting two injections that both cause sore arms and fatigue on the same day may make for a more miserable 48 hours, so some people prefer to stagger them for comfort reasons. That is a personal preference, not a medical necessity.

Why Age Recommendations Vary Around the World

In the United States, the CDC recommends Shingrix for all adults aged 50 and older, and for adults 19 and older who are immunocompromised. But cross the Atlantic and the picture gets complicated. Among the 17 EU countries that have adopted shingles vaccination recommendations, about a third recommend starting at 50, about 30% start at 60, and about 35% wait until 65.¹⁴ Ten EU countries have no formal recommendation at all. Only seven of the 17 recommending countries offer the vaccine free of charge.

These discrepancies are not really about disagreements over the science. They reflect different cost-effectiveness thresholds, healthcare budgets, and policy priorities. A meta-analysis of 37 cost-effectiveness studies found that Shingrix was consistently cost-effective for adults in the 60-to-79 age range, with stronger economic justification at older ages where the disease burden is highest.¹⁵ Countries that start at 65 are essentially saying the vaccine is worth it, but we cannot afford to cover everyone from 50, so we are targeting the group with the highest risk. That is a budget decision, not a medical one.

The underlying biology is clear on why age matters. The immune system’s ability to keep the varicella-zoster virus dormant declines with age, and this decline accelerates significantly in the 50s and beyond.¹⁶ The vaccine works by revving up the specific arm of the immune system responsible for keeping the virus in check. But the strength and duration of that boost is itself a function of age: vaccinate at 50 and the immune response tends to be robust and lasting; vaccinate at 80 and the response is weaker. This creates a paradox where the people who need the vaccine most are the ones who respond to it least well, although even in the oldest age groups the benefit clearly outweighs doing nothing.

Should Younger Adults at Higher Risk Be Vaccinated?

Shingles is not exclusively a disease of older adults. People with asthma face about a 24% higher risk, and those with chronic obstructive pulmonary disease see their risk elevated by roughly 41% compared to healthy controls.¹⁷ Other conditions that raise shingles risk in people under 50 include diabetes, autoimmune diseases, and any condition or treatment that suppresses the immune system.

Current U.S. guidelines already cover immunocompromised adults as young as 19, but for younger adults whose elevated risk comes from conditions like asthma or COPD rather than outright immunosuppression, the evidence is thinner. Most of the large efficacy trials enrolled people 50 and older, so there is limited data on how well the vaccine works in a 35-year-old with moderate asthma. Research into this gap is ongoing, and some experts have argued that vaccination programs should expand to include younger adults with chronic conditions that raise shingles risk. For now, the decision for a younger adult who does not meet the immunocompromised criteria is one to make with a doctor, weighing individual risk factors against the lack of formal guideline coverage.

How Shingrix Actually Generates Long-Lasting Immunity

Part of the reason Shingrix holds up so well over time is its adjuvant system, a combination of ingredients designed to amplify and shape the immune response beyond what the viral protein alone could achieve. The vaccine contains a single protein from the varicella-zoster virus paired with an adjuvant that pushes the immune system to produce both antibodies and a particular type of T cell that can perform multiple defensive functions simultaneously.¹⁸ These multitasking T cells, sometimes called polyfunctional T cells, are thought to be a major reason the vaccine maintains high efficacy for years rather than fading quickly. The adjuvant is also likely responsible for the vaccine’s notable reactogenicity: the same mechanism that fires up a strong, durable immune response is the one that makes your arm sore and leaves you fatigued for a couple of days.

Adherence Gaps and Who Falls Through the Cracks

Even a vaccine that only requires two lifetime doses has an adherence problem when nearly 30% of people who start the series do not finish it within six months. The real-world data on this are sobering. Among the over 700,000 adults tracked in one U.S. study, younger adults, Black and Hispanic patients, people with lower incomes, and those with commercial insurance rather than Medicare were all less likely to complete the series.¹ Some of those disparities reflect access: cost, pharmacy availability, the ability to take a day off if side effects hit hard. Others reflect the tolerability concerns discussed earlier. The vaccine’s short-term unpleasantness and the perception that shingles “isn’t that bad” combine to create a situation where people who would benefit most are least likely to finish the course.

If you received your first Shingrix dose months or even years ago and never went back for the second, you do not need to start over. The CDC advises simply getting the second dose as soon as practical, regardless of how much time has passed. That single act is probably worth more, protection-wise, than any future booster is likely to be.